Lonza, a global leader in biological and chemical manufacturing, and Kodiak Sciences Inc., a biopharmaceutical company designing and developing novel therapies for the treatment of retinal disease, announced today agreements for the clinical supply of Kodiak’s therapeutic candidates. Under the agreement, Lonza will manufacture material at multiple sites, including Slough (UK), Visp (CH) and Nansha (CN). Retinal diseases, such as age-related macular degeneration (AMD), cause blindness by damaging the retina, typically in those over 50 years of age. As the…